Abstract:
Provided by the present invention is bitter gourd leaching liquor which has excellent palatability and appealability by being in harmony with the unique bitter taste of a bitter gourd and has excellent anti-oxidative activity by containing enough bioactive substance in the bitter gourd. A producing method of the bitter gourd leaching liquor according to the present invention is able to produce the bitter gourd leaching liquor which increases the anti-oxidative activity and improves the palatability and the appealability in order to be more suitable for a consumer by utilizing the unique bitter taste of the bitter gourd. Bitter gourd leaching liquor which is produced in the alcohol content of 16% among various kinds of bitter gourd leaching liquor of the present invention is able to replace soju (Korean distilled liquor) as liquor of low alcohol content. Bitter gourd leaching liquor which is produced in the alcohol content of 38% is able to replace hard liquor. The bitter gourd liquor according to the present invention has an excellent function which corresponds to the recent trend of healthy liquor by having excellent anti-oxidative activity and expands the utilization of a bitter gourd by utilizing the bitter taste of the bitter gourd which has low usability because of the bitter taste.
Abstract:
본 발명은 DPPH 라디칼 소거활성, ABTs - ㆍ 라디칼 소거활성, 환원력 및 FRAP 활성이 가장 우수하면서도 관능적인 면에서 일반식혜와 커다란 차이점을 보이지 않아 건강을 지향하는 현대인들에게 새로운 기능성 음료로서 활용될 수 있는 대나무 잎 추출물과 백미와 흑미를 중량비율로 2 : 1로 배합하여 제조한 기능성 식혜를 제공하기 위한 것이다.
Abstract:
PURPOSE: A novel Bacillus CSY191 is provided to effectively suppress the growth of microorganisms and to ensure anticancer activity. CONSTITUTION: A Bacillus subtilis CSY191(deposit number KACC91473P) has acid resistance, bile acid tolerance, and antibacterial property against to food borne microbes. The food borne microbes are Escherichia coli, Pseudomonas aeruginosa, Salmonella enterica, Salmonella enteritidis, Salmonella typhymurium, Shigella flexineri, Shigella sonnei, Bacillu scereus, Listeria ivanovii, Listeria monocytogenes, Stephylococcus aureus or Stephyiococcus epiderimidis. A probiotic formulation contains the Bacillus subtilis CSY191(deposit number KACC91473P) of culture thereof as an active ingredient. A composition with cancer cell toxicity contains the strain or culture thereof as an active ingredient.